Click the cover to download report highlights
Enterprise EHR Foundation
AI support for clinical documentation is up this month, as PHTI finds that health providers and insurers lead AI efforts with this focus. And real-world data (RWD) have transitioned from niche applications to core infrastructure across the broad healthcare ecosystem, spanning the life sciences, media, provider, payer, and financial services markets, according to a Health Advances landscape analysis.
Healthcare Analytics and Intelligence
KLAS Research highlight three key market shifts are underway in ambient intelligence: (1) EHR offerings are resetting price and integration expectations; (2) expanded functionality is now necessary for differentiation; (3) buying decisions are moving toward more deliberate long-term platform evaluations. And ophthalmologists from UK, China, and Singapore present the case that healthcare needs a new role of the clinician-AI scientist who links clinical needs with technical solutions: identifies clinical problems, leads the design and validation of AI tools, and oversees their ethical implementation.
Consumer Health and Technology
Longevity medicine is up, as Northwestern ($5,500 a year) and Mayo Clinic Jacksonville ($45,000) open cash-pay clinics, though Northwestern saw only about 150 patients last year. Wearables are up as well, moving from tracking to treating, with Happy Health claiming the first FDA-cleared cuffless blood pressure ring. And a pair of papers warn AI harms are hard to see: Vanderbilt found chatbot-worsened psychosis concentrated among first-episode patients (61%), and researchers note such harms leave no record outside the platform.
Stakeholders
PBM concentration is up, with the top four controlling 75% of the market, up from 70% in 2022. Value-based care remains stalled, as a report from EY finds 40% of employers have no value-based arrangements and just 3% have more than 30% of spending in them, so employers are building their own condition-specific models. And brand bias is up in AI drug recommendations, with five leading models picking a single product 97.5% of the time, usually the original brand over cheaper generics.